{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:39:45Z","timestamp":1787981985237,"version":"build-2784847793"},"reference-count":46,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The emergence of immune checkpoint inhibitors has revolutionized the landscape of cancer treatment in the modern era. However, cutaneous immune\u2010related adverse events (cirAEs) are common, significantly affecting patients' quality of life and often leading to treatment discontinuation, which may compromise oncological outcomes. Dupilumab, an immunoglobulin G4 (IgG4) human monoclonal antibody targeting interleukin (IL)\u20104 and IL\u201013 receptors, is widely used for dermatologic conditions but remains unapproved for cirAEs due to the limited and scattered supporting evidence. This review aimed to summarize the available evidence regarding the use of dupilumab for the management of cirAEs. A systematic review was conducted using MEDLINE\/PubMed, Scopus, and Web of Science in adherence to the Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses (PRISMA) guidelines. In total, 25 publications met the eligibility criteria and were included, reporting 136 patients who were diagnosed with 140 cirAEs and were treated with dupilumab. The most frequently treated cirAEs were eczematous rashes, bullous pemphigoid, and maculopapular\/morbilliform rashes. Dupilumab was found to be highly effective, with most patients achieving complete or partial responses, even when affected by two concomitant cirAEs. An acceptable safety profile was demonstrated regarding both adverse events and oncological safety, with no additional concerns to be raised. The findings may be encouraging but are limited by the relatively small number of patients treated and the nature of the included studies, with most of them being case reports and case series. More research is warranted, along with more clinical studies, prospective in design, focused on relevant clinical outcomes of this dupilumab\u2010treated subset of patients.<\/jats:p>","DOI":"10.1111\/ijd.17850","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:46:01Z","timestamp":1747356361000},"page":"1825-1832","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Dupilumab for the Treatment of Cutaneous Immune\u2010Related Adverse Events: A Systematic Review"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7139","authenticated-orcid":false,"given":"Ioannis\u2010Alexios","family":"Koumprentziotis","sequence":"first","affiliation":[{"name":"First Department of Dermatology \u201cAndreas Sygros\u201d Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Niforou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology \u201cAndreas Sygros\u201d Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School  Athens Greece"},{"name":"Department of Hygiene, Epidemiology and Medical Statistics School of Medicine, National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-0762","authenticated-orcid":false,"given":"Antonios","family":"Tsimpidakis","sequence":"additional","affiliation":[{"name":"First Department of Dermatology \u201cAndreas Sygros\u201d Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Oncology Department Queen's Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stratigos","sequence":"additional","affiliation":[{"name":"First Department of Dermatology \u201cAndreas Sygros\u201d Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-9152","authenticated-orcid":false,"given":"Vasiliki","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology \u201cAndreas Sygros\u201d Hospital for Skin Diseases, National and Kapodistrian University of Athens, Medical School  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(22)00197\u20108"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030320"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17855"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02786"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072084"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21781"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20282"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040634"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0682"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16538"},{"key":"e_1_2_7_16_1","first-page":"28","article-title":"A Case of Eruptive Keratoacanthomas and Lichen Planus Secondary to Nivolumab Treatment for Stage IV Melanoma","volume":"57","author":"Alicea D. S.","year":"2024","journal-title":"Journal of the American Academy of Dermatology Case Reports"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17626"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.5070\/D328257396"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19707"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241297551"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","DOI":"10.1177\/2050313X231195462","article-title":"Dupilumab as a Treatment for Cutaneous Immune\u2010Related Adverse Events Induced by Immune Checkpoint Inhibitors: A Case Series and Review of the Literature","volume":"11","author":"Fournier C.","year":"2023","journal-title":"SAGE Open Medical Case Reports"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15340"},{"key":"e_1_2_7_24_1","article-title":"Long\u2010Term Mortality Outcomes Among Immunotherapy Recipients Treated With Dupilumab for the Management of Cutaneous Immune\u2010Related Adverse Events","volume":"2025","author":"Khattab S.","year":"2025","journal-title":"medRxiv"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14383"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.5070\/D327955136"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06548-4"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007324"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16714"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19369"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.05.004"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad164"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.01.029"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad149"},{"issue":"3","key":"e_1_2_7_36_1","article-title":"Dupilumab for Cancer\u2010Associated Refractory Pruritus","volume":"2","author":"Talmon A.","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_123_23"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.31743"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.05.036"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3431"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.12.018"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15628"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.002"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.028"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0636-9"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2043-6"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062998"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17850","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.17850","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:41:14Z","timestamp":1778859674000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/ijd.17850"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17850","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"2025-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}